Arcutis BiotherapeuticsARQT
About: Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Employees: 296
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
490% more call options, than puts
Call options by funds: $5.83M | Put options by funds: $989K
50% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 48
13% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 30
1% more funds holding
Funds holding: 184 [Q2] → 186 (+2) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
1% less capital invested
Capital invested by funds: $1.23B [Q2] → $1.21B (-$16.8M) [Q3]
2.81% less ownership
Funds ownership: 113.83% [Q2] → 111.02% (-2.81%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Mizuho Uy Ear 50% 1-year accuracy 5 / 10 met price target | 45%upside $20 | Outperform Maintained | 7 Jan 2025 |
HC Wainwright & Co. Douglas Tsao 45% 1-year accuracy 76 / 168 met price target | 38%upside $19 | Buy Initiated | 30 Dec 2024 |
Needham Serge Belanger 45% 1-year accuracy 56 / 124 met price target | 30%upside $18 | Buy Reiterated | 7 Nov 2024 |
Financial journalist opinion
Based on 4 articles about ARQT published over the past 30 days